A recent phase @ trial demonstrated a trend toward improved overall survival ( OS ) with decitabine , a hypomethylating agent , compared with treatment choice of either cytarabine or supportive care ( @ months , @ % CI : @-@ @ vs @ months , @ % CI : @-@ @ , respectively ) in older adults with newly diagnosed AML .